Sonnet BioTherapeutics Holdings Inc (SONN)

Overview News Price History Why SONN Down? Discussions Forecast Stock Split

Sonnet BioTherapeutics Holdings Inc stock is currently priced at $1.8141, with a 24-hour trading volume of 6,834. It has seen a +7.03% increased in the last 24 hours and a -15.23% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.72 pivot point. If it approaches the $1.81 resistance level, significant changes may occur.

Sonnet BioTherapeutics Holdings Inc Stock (SONN) Financials Data

Sonnet BioTherapeutics Holdings Inc (SONN) Revenue 2024

SONN reported a revenue (TTM) of $129.20 thousand for the quarter ending December 31, 2023, a -49.81% decline year-over-year.

Sonnet BioTherapeutics Holdings Inc (SONN) Net Income 2024

SONN net income (TTM) was -$14.46 million for the quarter ending December 31, 2023, a +50.25% increase year-over-year.

Sonnet BioTherapeutics Holdings Inc (SONN) Cash Flow 2024

SONN recorded a free cash flow (TTM) of -$18.52 million for the quarter ending December 31, 2023, a +29.55% increase year-over-year.

Sonnet BioTherapeutics Holdings Inc (SONN) Earnings per Share 2024

SONN earnings per share (TTM) was -$12.75 for the quarter ending December 31, 2023, a +90.66% growth year-over-year.

Sonnet BioTherapeutics Holdings Inc Stock (SONN) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Dyrness Albert D.	Director	May 30 '23	Buy	0.47	23,255	10,883	28,962
Bhatt Nailesh	Director	May 17 '23	Buy	0.23	25,000	5,800	30,733
Mohan Pankaj	Chairman, President and CEO	May 15 '23	Buy	0.22	371,600	82,867	553,331

Sonnet BioTherapeutics Holdings Inc Stock (SONN) Latest News

Dow Falls Over 100 Points; Alphabet Shares Tumble After Q3 Results

Benzinga

Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Benzinga

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer and is under phase 1 trial. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy and is under Phase Ib/IIa study; and SON-1210, a bispecific compound developed for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.